United Therapeutics Licenses Arena’s Ralinepag for US$800 M Upfront
By Michelle Liu
Pharma Deals Review: Vol 2018 Issue 11 (Table of Contents)
Published: 24 Nov-2018
DOI: 10.3833/pdr.v2018.i11.2373 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
United Therapeutics has signed an agreement for the worldwide licence to develop, manufacture and commercialise Arena’s ralinepag for the treatment of pulmonary arterial hypertension (PAH)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS